TEVA Jan 2026 10.000 call
- Business Wire
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
TEL AVIV, Israel & PARSIPPANY, N.J., May 29, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea.
- Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 21, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult pla
- GuruFocus.com
Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...
On May 16, 2024, Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), executed a sale of 28,135 shares of the company.
